Table 2.
Vision and health-related quality of life scores at baseline, the primary endpoint (6 months or treatment failure prior to 6 months), & the secondary endpoint (12 months or treatment failure between 6-12 months)
| Baseline | 1° Endpoint | 2° Endpoint | Wilcoxon p-valuea | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Median | IQR | Median | IQR | Median | IQR | 0-1° | 1°-2° | 0-2° | |
| Vision-related QOL b | |||||||||
| NEI-VFQ | 61.9 | 48.2-80.3 | 81.5 | 68.6-93.4 | 84.0 | 70.2-95.9 | <0.001 | 0.07 | <0.001 |
| IND-VFQ | 69.6 | 42.0-80.2 | 91.1 | 76.2-100.0 | 92.8 | 76.9-100.0 | <0.001 | 0.02 | <0.001 |
| Health-related QOL c | |||||||||
| PCS | 44.1 | 39.4-52.1 | 52.2 | 44.8-57.2 | 52.4 | 45.1-57.1 | <0.001 | 0.11 | <0.001 |
| MCS | 41.0 | 36.6-48.8 | 47.1 | 38.3-53.1 | 46.4 | 39.9-57.0 | <0.001 | 0.99 | 0.002 |
a
Reported p-values are from Wilcoxon signed rank tests
b
Vision-related quality of life scales: NEI-VFQ - National Eye Institute Visual Functioning Questionnaire; IND-VFQ - Indian Vision Function Questionnaire (Indian participants only)
c
Health-related quality of life scales: PCS - physical component score of the Medical Outcomes Study 36-Item Short Form Survey (PCS SF-36v2); MCS - mental component score of the Medical Outcomes Study 36-Item Short Form Survey (MCS SF-36v2)